FDAnews Drug Daily Bulletin

BIOSANTE REPORTS PRODUCT DEVELOPMENT HIGHLIGHTS AND THIRD QUARTER 2005 FINANCIAL RESULTS

Nov. 14, 2005
A A

BioSante Pharmaceuticals, Inc. (AMEX:BPA) reported product development highlights and financial results for the third quarter ended September 30, 2005. "We achieved milestones across our key clinical programs this quarter. We presented positive Phase III data for Bio-E-Gel(TM), licensed three patents that cover the use of testosterone (LibiGel(TM)) to treat hypoactive sexual desire disorder in women on hormone contraception, and entered into an allergy licensing option agreement for our CaP nanotechnology," said Stephen M. Simes, BioSante's president and chief executive officer.
Small Times